The Canadian government has granted a startup permission to export substances derived from psychedelics to Australia for medicinal purposes. Optimi Health Corp. has been given the responsibility of exporting pills containing psilocybin, an extract from magic mushrooms, and MDMA, as sanctioned by the health department.
Beyond the local demand for magic mushrooms in Ontario, other countries are following Canada’s lead and starting to investigate and approve the use of serotonergic substances for medical applications.
Feel free to buy psychedelics online in Canada securely and discover your innate potential through trustworthy sources.
[toc]Main Takeaways:
- Optimi Health, a Vancouver-based startup, has been issued a drug establishment license to export magic mushroom pills to Australia.
- Australia allows licenced psychiatrists to use magic mushrooms in the treatment of chronic depression.
- The treatment consists of three sessions spread out over five to eight weeks, with each session lasting about eight hours.
The Rise of Psilocybin Capsules in Canada
Optimi, a small Vancouver-based firm, aims to use its certification to broaden the pharmaceutical market for psychedelic drugs and secure a first-mover advantage.
Seven companies have exported psilocybin, MDMA, or both, but only for clinical trials. A spokesperson from Canada’s health department couldn’t confirm if these exports were for standard patient use and chose not to reveal the companies for security reasons.
This accomplishment places Optimi among a limited group of global suppliers, with the current market tending more towards clinical use rather than recreational use.
What’s in the Pill?
Although the company has not disclosed the specific mushroom strain used in the pill, they do work with a range of strains including Albino Penis Envy, among others.
Optimi has established a 20,000-square-foot facility in Princeton, British Columbia, to cultivate, test, and extract its psychedelic mushrooms. This quaint town, home to about 3,000 inhabitants, lies a three-hour drive east of Vancouver.
The Connection Between Australia and Psychedelic Mushrooms
It’s projected that 1 in every 5 Australians between the ages of 16 and 85 may suffer from a mental disorder. Post-traumatic stress disorder (PTSD) is likely to impact 11% of Australians at some point, and anxiety disorders are common among 17% of the population.
While a variety of treatment methods exist for mental health issues, not all are effective for each individual. Those who do not respond to certain treatments may struggle to find a beneficial approach, thereby enhancing their vulnerability.
Explaining the Procedure
Australia has been a leader in the use of psilocybin, allowing licensed psychiatrists to use this controlled substance in the treatment of PTSD and treatment-resistant depression.
In a ground-breaking move in February, Australia’s Therapeutic Goods Administration (TGA) reclassified MDMA and psychedelic mushrooms for therapeutic purposes. The TGA claimed these substances are safe when used in a medically managed environment for patients with severe mental health disorders.
This advancement has been a game-changer for many mental health professionals and researchers. The use of these substances will be strictly monitored; this is not just about taking a pill and leaving.
The standard treatment usually involves three sessions spread over five to eight weeks. Each session lasts around eight hours, with the therapist remaining with the patient during the entire duration.
Canada’s Role in Psilocybin Research
Canada has come to the forefront as a major center for psilocybin research, greatly expanding our understanding of this compound. Health Canada, in conjunction with various institutions, is spearheading the study of the therapeutic potential of psilocybin for a range of mental health conditions.
Research institutions no longer need to label these substances as illegal or rely on unauthorized dispensaries or mushroom shops. The government now permits select institutions to grow psychedelic mushrooms for research purposes.
The increased access to substances previously deemed harmful allows researchers to deepen their understanding of the potential benefits these could offer to many individuals.
A Recurring Trends
The potential of this field was first realized in the 1950s as a solution to mental health problems and substance dependency, including alcohol addiction. English psychiatrist Humphry Osmond and Canadian biochemist Abram Hoffer pioneered this groundbreaking research at Weyburn, The Saskatchewan Mental Hospital. The institution saw significant progress under the leadership of then-premier Tommy Douglas, who granted the medical community considerable freedom to explore their medical hypotheses.
Dr. Osmond and Dr. Hoffer began investigations with LSD, mescaline, and peyote as potential alternatives to the harsh methods of electroshock and lobotomy. Their research evolved in unexpected ways, with the pair recommending that doctors, nurses, and support staff try these drugs.
Research at Canadian Institutes of Health
Through the Institute of Neurosciences, Mental Health and Addiction, the Canadian Institutes of Health Research is funding three clinical trials to examine the therapeutic effectiveness and safety of psilocybin-assisted psychotherapy:
| Project Type | Study Focus | Research Institution | Principal Investigator | Project Budget |
| A randomized controlled trial | Psychological distress at end-of-life in patients with advanced-stage cancer | University of Toronto | Sarah Hales | $928,643 |
| Mechanisms supporting psilocybin psychotherapy for treating alcohol use disorder | Alcohol use disorder | University of Calgary | Leah Mayo | $1,000,000 |
| A randomized phase II clinical trial contrasting single versus dual psychedelic doses | Treatment-resistant depression | University of Toronto | Joshua Rosenblat | $1,000,000 |
This research funding will enable a deeper understanding of the benefits of regulated substances. The Canadian Drugs and Substances Strategy (CDSS), initiated by the Government of Canada, has facilitated this funding.
Further Psychedelic Research
Psychiatrists in Vancouver have initiated a phase III clinical trial of MDMA, better known as ecstasy, for the treatment of post-traumatic stress disorder (PTSD). The treatment includes three eight-hour sessions with MDMA, scheduled a month apart, and nine 90-minute sessions without the drug. Researchers consider this trial historically important as it marks the first clinical exploration of an illegal
This is the first time in over forty years that such a psychedelic substance has been studied.
A Comprehensive Look at Psilocybin
Psilocybin, a psychedelic compound that naturally occurs in certain types of mushrooms, transforms into psilocin when ingested. This psilocin stimulates the serotonin 5-HT2a receptors, which are positioned on the cortical pyramidal cells in the brain. These cells serve as the main processing centers.
Local authorities are investigating the potential of this substance to alleviate depression, anxiety, addiction, and end-of-life distress by encouraging introspection and promoting spiritual enlightenment.
Why is it Potentially Beneficial for Depression, PTSD, and Other Conditions?
This substance’s active ingredient impacts several areas of the brain, making it potentially beneficial for a variety of mental health conditions. Some patients in Canada and Australia have already undergone this treatment, and the reported results are promising, with minor side effects such as temporary anxiety or elevated blood pressure.
Impact on Neurobiology
- Activation of Serotonin Receptor: This substance partially activates serotonin receptors, particularly the 5-HT2A subtype, which is vital for emotional processing and mood management.
- Modulation of Default Mode Network (DMN): The activity in the DMN is reduced, promoting introspection, mitigating rigid thought patterns, and enhancing emotional adaptability.
- Stimulation of Prefrontal and Limbic Areas: The antidepressant effects of this substance stem from its influence on the prefrontal and limbic regions of the brain, including the amygdala. In instances of depression, individuals typically display decreased responsiveness to emotional stimuli. The substance increases the response to positive emotional stimuli in the right amygdala while reducing or normalizing the response to negative or neutral emotional stimuli.
Effects on Psychology and Emotion:
- Fostering Positive Mood States: It stimulates feelings of euphoria, interconnectedness, and emotional openness during and following the experience.
- Enhanced Emotional Processing: The psychedelic journey may facilitate individuals in safely facing and processing deeply embedded emotions, traumatic memories, or existential concerns in a supportive context.
- Spiritual and Existential Insights: Research from Johns Hopkins University and Imperial College Research suggests that London contributes to long-term positive changes, such as increased happiness, improved life satisfaction, and spiritual growth.
What Products are Available at Your Local Magic Mushroom Store?
Interested in exploring how these substances can impact your mental health? Visit magic mushroom stores to find the right product for you.
| Product | Quantity | Potency | Benefits |
| Evoke – Medicinal Mushrooms | 20 | 100mg or 200mg | Improves mood, triggers creative thinking, and amplifies productivity and focus |
| Ground Sounds – Microdose Capsules – Super Freak | 30 | 50mg, 100mg, and 250mg | Boosts wellness and enhances life quality |
| Kind Stranger – Microdose Capsules – Sidekick | 30 | 100mg | Promotes clear thinking, creativity, and concentration. Contains a powerful mix of clinical-strength adaptogenic herbs |
| Osmosis – Brain Boost | 30 | 100mg or 200mg | Provides cognitive and energy benefits |
International Recognition of Psilocybin
Canada is not the only nation supporting the use of magic mushrooms for mental health treatments. Other countries like Australia are also embracing these hallucinogens to tackle conditions such as depression and PTSD. They are obtaining top-quality psychedelic capsules from trustworthy sources. Under proper guidance, patients can significantly improve their life quality. Buy Shrooms Online Canada, a magic mushroom supplier, offers a variety of products, from tablets to LSD edibles.
Frequently Asked Questions
What are the similarities between psilocybin and MDMA?
Both psilocybin and MDMA have therapeutic potentials by enhancing mental well-being. Psilocybin interacts with serotonin 2A receptors and is effective in treating depression and addiction.
Conversely, MDMA promotes empathy and is beneficial in PTSD therapy. It shows promise in improving emotional processing and despite being classified as a controlled substance.
Is this treatment option available to all Australians?
No. In Australia, individuals need to undergo an assessment to ascertain their eligibility for using the substance. Factors such as pre-existing heart conditions, a history of psychosis, and others are taken into account during this evaluation. The treatment is exclusively available to those patients who haven’t shown improvements with conventional treatments for conditions like depression, anxiety, or PTSD.
What implications does Canada exporting mushrooms have?
Canada is setting itself up to lead the psychedelics market, much like its position with cannabis. This move could encourage more companies to produce top-quality products. As a result, Canada might establish itself as a leader in the hallucinogen market, strengthen its economy, and make treatments more accessible for other countries. It could also discourage other countries from obtaining their hallucinogens from illegal dispensaries or providers, thereby ensuring safety.
Articles That Might Interest You:
